Newsletter Subject

COVID Vaccine Bonus: It May Protect Against the Common Cold, Study Finds

From

inhresearch.com

Email Address

mail@mb.inhresearch.com

Sent On

Sun, May 23, 2021 04:16 PM

Email Preheader Text

 ‌ You need to read this. that completely halted aging in mice. Over the course of 12 month

 ‌ You need to read this. [Health Watch] Sponsored Content Every symptom of “old age”—GONE Scientists at Washington University School of Medicine in St. Louis have unearthed [a single natural compound]( that completely halted aging in mice. Over the course of 12 months of treatment, [every symptom of “old age” was simply REVERSED](. [mouse]( Big Pharma is chomping at the bit to cash in on this breakthrough. But there’s one [big secret]( they don’t want you to know… This age-erasing, natural substance is ALREADY available. And today, one former high-ranking government researcher is [releasing all the details](. [Click here]( --------------------------------------------------------------- COVID Vaccine Bonus: It May Protect Against the Common Cold, Study Finds People who get the Pfizer or Moderna COVID-19 vaccines produce immune system cells that protect against the common cold. That’s the conclusion a new study by researchers at Johns Hopkins Medicine. The scientists took blood samples from 30 healthy subjects before and after they had two doses of one or the other of the vaccines. The researchers then analyzed immune cells in the samples known at CD4+ T cells. They are also known as “helper” cells. They get their nickname because they help other immune cells respond to invading viruses. Helper cells defend against viruses by sending out chemical messengers that attract another type of immune cell called killer T cells. Killer T cells remove virus-infected cells from the body. COVID Shots Protect Against Variants… And Possibly Colds There was good news when scientists analyzed helper cells in subjects after they were fully vaccinated. Researchers found that their helper cells recognized coronavirus variants from the U.K. and South Africa. That means current vaccines should remain effective as these strains become prevalent. And the scientists found more good news… The helper cells produced by the vaccines protect against a prevalent form of the common cold. It’s called HCoV-NL63. It’s related to COVID-19. It’s a type of cold that primarily strikes seniors and children. It usually causes only mild symptoms that are typically associated with colds. But in rare cases, it can lead to pneumonia or bronchitis. The researchers don’t know why the vaccines protect against this type of cold. But they think the cold virus shares some peptides with the COVID-19 virus. Peptides are the building blocks of proteins that make up a virus. Dr. Joel Blankson is senior author of the study. He is a professor at the Johns Hopkins School of Medicine. “We suspect that HCoV-NL63 may have more (peptides) in common with COVID-19 than other common cold viruses,” said. The study did not look at people who took the other shot that is available in the U.S., the vaccine from Johnson & Johnson. So we don’t know if the J&J shot offers similar cold protection. --------------------------------------------------------------- Recommended Content Second pandemic lurking behind COVID? Have you seen [this urgent warning]( It’s from a cancer expert at one of the nation’s top medical centers. He went on record in The New York Times stating that he and his colleagues believe 2021 will bring a second pandemic… And today, one former NIH researcher is revealing [all the details]( on ways to help you prepare—to help protect yourself from this potential threat. Watch this urgent video now by [clicking here](. [Click here]( --------------------------------------------------------------- Vaccines Can Fight Diseases Other Than Their Target It may seem strange that a vaccine designed to stop one illness can protect you from another. This is called “cross-protection.” Actually, it’s not unusual. One of the first examples of cross-protection was noted by Russian researchers in the 1950s. They found that people who got the polio vaccine were less likely to get the flu. In the 1960s, the tuberculosis vaccine was found to protect against bladder cancer. It is still used to treat bladder cancer today. And a recent study in the Netherlands found that people who received the flu shot are 39% less likely to get infected with coronavirus than people who did not get the flu vaccine. The bottom line? The Pfizer and Moderna COVID vaccines appear to work well against coronavirus variants—and they may provide bonus protection against the common cold. [Get the Latest Breaking News About Coronavirus Here]( - The Alarming COVID Vaccine Side Effect Every Woman Should Know About. It’s sending some women running to their doctors into a panic. [Click HERE to read more.]( - J&J Vaccine Blood Clots: Get the Facts. Is this potentially deadly side effect something you should worry about? [Click HERE to read more.]( - Omega-3s Cut COVID Death Risk, Study Finds. Most people take fish oil for heart health. But new research shows it could offer an important added benefit during the pandemic. [Click HERE to read more.]( In Good Health, Amanda Angelini Director The Institute for Natural Healing [References Available Here.]( --------------------------------------------------------------- © 2021 OmniVista Health Media, LLC. All Rights Reserved. For more from OmniVista Health Media, LLC, [visit our website](. To end your free subscription, click here: [Unsubscribe]( Health Watch may be republished with its links intact by non-commercial entities. Health Watch may not be republished for commercial purposes without written permission. This information is offered as a general guideline, not one-size-fits-all medical advice. Talk to your doctor before making any changes in your personal health care regimen. To manage your subscription by mail or for any other subscription issues, write us at: Order Processing Center Attn: Customer Service P.O. Box 925 Frederick, MD 21705 USA

Marketing emails from inhresearch.com

View More
Sent On

11/08/2022

Sent On

11/08/2022

Sent On

11/08/2022

Sent On

10/08/2022

Sent On

10/08/2022

Sent On

09/08/2022

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.